Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

Firefly Neuroscience, an AI-focused precision neuroscience company listed on NASDAQ as AIFF, has identified a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using its FDA-510(k)-cleared Evoke System. The discovery stems from the company’s ongoing public-private partnership with the U.S. Department of War (DoW), aimed at assessing and treating active-duty service members and veterans with PTSD or Traumatic Brain Injury (TBI). The biomarker was uncovered through high-throughput analysis of multi-channel electroencephalogram (EEG) and Event-Related Potential (ERP) waveforms, enabled by Firefly’s deep learning architecture running on NVIDIA L40S GPU-accelerated infrastructure. The Evoke System’s dual-signal approach captures resting-state hyperarousal patterns and abnormal cognitive ERP responses, offering a more precise diagnostic tool for PTSD. PTSD affects approximately 13 million Americans annually, with military personnel disproportionately impacted—11-20% of Operation Iraqi Freedom and Enduring Freedom veterans experience PTSD each year. The economic burden of PTSD in the U.S. is estimated at $232.2 billion, with $42.7 billion attributed to the military population. Firefly’s Chief Technology Officer, Gil Issachar, stated that the AI models identified a consistent and reproducible electrophysiological pattern distinguishing PTSD patients from healthy controls. This discovery aligns with the company’s DoW deployment, providing military healthcare providers with a scientifically grounded neural signal for PTSD assessment. The breakthrough positions Firefly as the only company with both an active government brain health partnership and a validated neural signal marker for PTSD. CEO Greg Lipschitz highlighted the potential for the biomarker to expand commercial applications, including defense health, pharmaceutical partnerships, and clinical psychiatry, while supporting objective PTSD diagnostics for civilians and military populations alike.